Patents Examined by K. Cochrane Carlson
  • Patent number: 6001803
    Abstract: A pharmaceutical composition which comprises the c-kit ligand (KL) purified by applicants or produced by applicants' recombinant methods in combination with other hematopoietic factors and a pharmaceutically acceptable carrier is provided as well as methods of treating patients which comprise administering to the patient the pharmaceutical composition of this invention. This invention provides combination therapies using c-kit ligand (KL) and a purified c-kit ligand (KL) polypeptide, or a soluble fragment thereof and other hematopoietic factors. It also provides methods and compositions for ex-vivo use of KL alone or in combination therapy. A mutated KL antagonist is also described. Such an antagonist may also be a small molecule. Antisense nucleic acids to KL as therapeutics are also described. Lastly, compositions and methods are described that take advantage of the role of KL in germ cells, mast cells and melanocytes.
    Type: Grant
    Filed: October 20, 1994
    Date of Patent: December 14, 1999
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Peter Besmer, Jochen Buck, Malcolm A. S. Moore, Karl Nocka
  • Patent number: 5993798
    Abstract: The present invention provides a novel human cytokine termed Oncoinhibin. The protein Oncoinhibin is secreted by human erythroblastoid cells, has a molecular weight of approximately 28 kDa and exerts diverse neoplastic activity. The present invention also provides a method for treating neoplastic cells using human Oncoinhibin and a pharmaceutical composition comprised essentially of Oncoinhibin.
    Type: Grant
    Filed: August 1, 1994
    Date of Patent: November 30, 1999
    Assignee: Research Development Foundation
    Inventor: Bharat B. Aggarwal
  • Patent number: 5976872
    Abstract: This invention provides an isolated, animal nucleic acid molecule encoding the Brain Factor-1, Brain Factor-2 and Brain Factor-3. This invention also provides expression vectors containing these nucleic acid molecules, host vector systems containing the vectors and a method of producing the Brain factor comprising growing the host vector system under suitable conditions. This invention also provides a DNA vector which comprises the 5' nontranscribed region of the Brain Factor-1 gene, 3' nontranscribed region of the Brain Factor-1 gene and a gene of interest, linked operably.
    Type: Grant
    Filed: February 21, 1995
    Date of Patent: November 2, 1999
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Wufan Tao, Eseng Lai
  • Patent number: 5879910
    Abstract: The invention concerns hepatocyte growth factor (HGF) variants that compise an amino acid alteration at a site within the protease domain of HGF and retaining substantially full receptor binding affinity of the corresponding wild-type HGF.
    Type: Grant
    Filed: February 9, 1994
    Date of Patent: March 9, 1999
    Assignee: Genetech, Inc.
    Inventors: Paul J. Godowski, Natalie A. Lokker, Melanie R. Mark
  • Patent number: 5837811
    Abstract: A purified preparation of a polypeptide that is immunologically reactive with the monoclonal antibody produced by the hybridoma designated ATCC # HB 10319.
    Type: Grant
    Filed: March 28, 1994
    Date of Patent: November 17, 1998
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Paul J. Anderson, Michel Streuli, Stuart F. Schlossman
  • Patent number: 5750373
    Abstract: A method for selecting novel proteins such as growth hormone and antibody fragment variants having altered binding properties for their respective receptor molecules is provided. The method comprises fusing a gene encoding a protein of interest to the carboxy terminal domain of the gene III coat protein of the filamentous phage M13. The gene fusion is mutated to form a library of structurally related fusion proteins that are expressed in low quantity on the surface of a phagemid particle. Biological selection and screening are employed to identify novel ligands useful as drug candidates. Disclosed are preferred phagemid expression vectors and selected human growth hormone variants.
    Type: Grant
    Filed: April 30, 1993
    Date of Patent: May 12, 1998
    Assignee: Genentech, Inc.
    Inventors: Lisa J. Garrard, Dennis J. Henner, Steven Bass, Ronald Greene, Henry B. Lowman, James A. Wells, David J. Matthews
  • Patent number: 5744442
    Abstract: A method for decreasing metalloproteinase activity in a patient that comprises the step of administering to said patient a therapeutic composition comprising the cytokine oncostatin-M, or a biologically active fragment, mutant, analog or fusion construct thereof. Also, a method for increasing TIMP activity in a patient that comprises the step of administering to said patient a therapeutic composition comprising the cytokine oncostatin-M, or a biologically active fragment, mutant, analog or fusion construct thereof. In addition a method for inhibiting or treating progression of a tumor in a patient that comprises the step of administering to said patient a therapeutic composition comprising oncostatin-M, or a biologically active fragment, mutant, analog, or fusion construct thereof, said method being effective to inhibit invasion by a tumor cell through an extracellular space, extracellular matrix, basement membrane, interstitial tissue or connective tissue.
    Type: Grant
    Filed: August 26, 1992
    Date of Patent: April 28, 1998
    Assignees: Bristol Meyers Squibb Company, McMaster University
    Inventors: Carl D. Richards, Mohammed Shoyab, Jack Gauldie, Thomas Joseph Brown
  • Patent number: 5736363
    Abstract: Insulin-like Growth Factor II (IGF-II) analogues in which at least one of R37 and R38 is replaced with another amino add residue, the most preferred being IGF-II R37Q R38Q, can readily be produced in E. coli, unlike natural IGF-II, which is cleaved on secretion. The analogues retain activity on the type I and type II IGF receptors but have lower affinity for the insulin receptor; they are therefore more specific in their action.
    Type: Grant
    Filed: February 28, 1994
    Date of Patent: April 7, 1998
    Assignee: British Bio-technology Limited
    Inventors: Richard Mark Edwards, Lindsay Bawden
  • Patent number: 5736339
    Abstract: An assay for screening snake venom for the presence or absence of platelet aggregation inhibitors (PAIs) based on specific receptor binding is described. Using this assay, the identification and characterization of PAIs in a wide range of snake venom samples was accomplished. The isolated and purified PAI from several of these active snake venoms is described and characterized. In addition, PAIs lacking the Arg-Gly-Asp (RGD) adhesion sequence but containing K*-(G/Sar)-D wherein K* is a modified lysyl residue of the formulaR.sup.1.sub.2 N(CH.sub.2).sub.4 CHNHCO--wherein each R.sup.1 is independently H, alkyl(1-6C) or at most one R.sup.1 is R.sup.2 --C.dbd.NR.sup.3 wherein R.sup.2 is H, alkyl(1-6C) or is NR.sup.4.sub.2 in which each R.sup.4 is independently H or alkyl(1-6C) and R.sup.3 is H, alkyl(1-6C), phenyl or benzyl, or R.sub.2 --C.dbd.NR.sup.3 is a radical selected from the group consisting of: ##STR1## where m is an integer of 2-3, and each R.sup.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: April 7, 1998
    Assignee: COR Therapeutics, Inc.
    Inventors: Robert M. Scarborough, David Lawrence Wolf, Israel F. Charo
  • Patent number: 5714575
    Abstract: A family of stimuli-induced in particular stress or cold-shock induced genes and proteins are disclosed which have conserved amino acid domains. Nucleic acid sequences of the genes and the promoters are also described. Various utilities of the promoters and of the proteins are disclosed.
    Type: Grant
    Filed: March 1, 1994
    Date of Patent: February 3, 1998
    Assignee: The University of Medicine and Dentistry of New Jersey
    Inventors: Masayori Inouye, Pamela Jones, Jean-Pierre Etchegaray, Weining Jiang, N. Stephen Pollitt, Joel Goldstein
  • Patent number: 5695966
    Abstract: The ability to convert daunorubicin to doxorubicin can be conferred on a host cell by transformation with a recombinant vector comprising DNA encoding daunorubicin 14-hydroxylase. The host cell can then be used to produce doxorubicin.
    Type: Grant
    Filed: February 27, 1995
    Date of Patent: December 9, 1997
    Assignee: Pharmacia & Upjohn S.p.A.
    Inventors: Augusto Solari Inventi, Umberto Breme, Anna Luisa Colombo, Charles Richard Hutchinson, Sharee Otten, Claudio Scotti
  • Patent number: 5688662
    Abstract: A novel taste cell specific guanine nucleotide binding protein, gustducin, is disclosed as well as polynucleotide sequences encoding the .alpha. subunit of gustducin. Also disclosed are methods of modifying taste involving agents that inhibit or activate the gustducin .alpha. subunit, methods for identifying such taste modifying agents and various taste modifying agents.
    Type: Grant
    Filed: April 9, 1992
    Date of Patent: November 18, 1997
    Assignee: Linguagen Corporation
    Inventor: Robert F. Margolskee
  • Patent number: 5688666
    Abstract: A method for selecting novel proteins such as growth hormone variants having altered binding properties for a growth hormone receptor molecule is provided. The method comprises fusing a gene encoding a hormone to the carboxy terminal domain of the gene III coat protein of the filamentous phage M13. The gene fusion is mutated to form a library of structurally related fusion proteins that are expressed in low quantity on the surface of a phagemid particle. Biological selection and screening are employed to identify novel ligands useful as drug candidates. Disposed are preferred phagemid expression vectors and selected human growth hormone variants.
    Type: Grant
    Filed: January 14, 1994
    Date of Patent: November 18, 1997
    Assignee: Genentech, Inc.
    Inventors: Steven H. Bass, Ronald Greene, Henry B. Lowman, James A. Wells
  • Patent number: 5686288
    Abstract: A novel gene, huntingtin, is described, encoding huntingtin protein, recombinant vectors and hosts capable of expressing huntingtin. Methods for the diagnosis and treatment of Huntington's disease are also provided.
    Type: Grant
    Filed: May 20, 1994
    Date of Patent: November 11, 1997
    Assignee: The General Hospital Corporation
    Inventors: Marcy E. MacDonald, Christine M. Ambrose, Mabel P. Duyao, James F. Gusella
  • Patent number: 5683894
    Abstract: A method for producing pure, active, mature recombinant Nerve Growth Factor-beta is disclosed, as is the protein so produced.
    Type: Grant
    Filed: March 7, 1991
    Date of Patent: November 4, 1997
    Assignee: University of California
    Inventors: Robert H. Edwards, William J. Rutter
  • Patent number: 5681809
    Abstract: The present invention relates to antagonists of vertebrate growth hormones obtained by mutation of the third alpha helix of such proteins (especially bovine or human GHs). These mutants have growth inhibitory or other GH-antagonizing effects. These novel hormones may be administered exogenously to animals, or transgenic animals may be made that express the antagonist. Animals have been made which exhibited a reduced growth phenotype.
    Type: Grant
    Filed: September 26, 1994
    Date of Patent: October 28, 1997
    Assignee: Ohio University
    Inventors: John J. Kopchick, Wen Y. Chen
  • Patent number: 5665869
    Abstract: The present invention relates to a method for the production of a substantially protoporphyrin IX free hemoglobin solution comprising: rapidly heating a crude protoporphyrin IX-containing hemoglobin solution for a relatively short time and at a relatively high temperature to reduce protoporphyrin IX-containing hemoglobin to insignificant levels in said protoporphyrin IX-containing hemoglobin solution.
    Type: Grant
    Filed: November 15, 1993
    Date of Patent: September 9, 1997
    Assignee: Somatogen, Inc.
    Inventors: James R. Ryland, Maura-Ann H. Matthews, Ulrich P. Ernst, Daniel E. Houk, David W. Traylor, Lee R. Williams
  • Patent number: 5663305
    Abstract: The present invention provides analogs of animal somatotropins particularly with changes in the amino acids between residue 96 to 133 which are changed to reduce hydrophobicity or helical stability.
    Type: Grant
    Filed: December 29, 1994
    Date of Patent: September 2, 1997
    Assignee: The Upjohn Company
    Inventors: Sherwood Russ Lehrman, Henry A. Havel, Jody L. Tuls, Scott M. Plaisted, David N. Brems
  • Patent number: 5659013
    Abstract: New compounds that bind specifically to vascular permeability factor (VPF) are used in methods of targeting these compounds, which include effector molecules that are, e.g., toxic, radioactive, or serve as marker labels, for tumor cells and the associated blood vessel endothelial cells, based on the discovery that VPF concentrates selectively in the endothelium and basement membrane lining tumor-associated blood vessels to a far greater degree than in normal vessels. By targeting VPF rather than the tumor cells themselves, the invention avoids the problems of tumor heterogeneity and diffusion distance.
    Type: Grant
    Filed: October 24, 1994
    Date of Patent: August 19, 1997
    Assignee: Beth Israel Hospital Association
    Inventors: Donald R. Senger, Harold F. Dvorak
  • Patent number: 5656599
    Abstract: This invention relates to E2 trans-activation repressors which interfere with normal functioning of the native full-length E2 transcriptional activation protein of the papillomavirus. Native full-length E2 trans-activation protein activates transcription of papillomavirus only through binding to DNA, and it binds to DNA only in the form of a pre-formed homodimer--a pair of identical polypeptide subunits held together by non-covalent interactions. The E2 trans-activation repressors of this invention are proteins, polypeptides or other molecules that dimerize with full-length native E2 polypeptides to form inactive heterodimers, thus interfering with the formation of active homodimers comprising full-length native E2 polypeptides, thereby repressing papillomavirus transcription and replication. The E2 trans-activation repressors of this invention are advantageously used in the treatment of papillomavirus infections and their associated diseases.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: August 12, 1997
    Assignees: Biogen, Inc., New England Medical Center Hospitals, Inc.
    Inventors: Elliot J. Androphy, James G. Barsoum